Evaluation of the Pharmacokinetics of Abiraterone Acetate and Abiraterone Following Single-Dose Administration of Abiraterone Acetate to Healthy Subjects
- 39 Downloads
Background and Objective
Following oral administration of abiraterone acetate, the parent compound abiraterone acetate is rapidly metabolized to abiraterone. To our knowledge, bioanalytical methods to date have not been able to detect the parent compound in human plasma, and bioassay was only performed on the metabolite. A highly sensitive bioanalytical method was developed and validated to measure plasma concentrations of the parent compound. In this study, both analytes were assayed and used to evaluate the full pharmacokinetic profile of abiraterone acetate tablets.
This was an open-label, single-dose, one-period, one-treatment, pharmacokinetic study performed in 18 healthy subjects. Each subject was administered four tablets (corresponding to a total dose of 1000 mg) of abiraterone acetate. Blood samples for pharmacokinetic analysis were collected up to 60 h post-dose. Subjects’ plasma concentrations for abiraterone acetate were assayed using highly sensitive validated bioanalytical methods with a lower limit of quantitation (LLOQ) of 0.5 pg/ml for abiraterone acetate and 0.1 ng/ml for abiraterone. Safety assessments were performed throughout the study.
The pharmacokinetic results for abiraterone acetate showed a mean for the maximum plasma concentration (Cmax) of 54.67 ± 68.30 pg/ml, and a median time to maximum concentrations (tmax) of 5.53 h (range 2.67–35.00 h). The means for area under the concentration-time curve (AUC) from time 0 h to infinity (AUCinf) and AUC from time zero h to the time of the last measurable abiraterone acetate concentrations (AUCt) were 386.13 ± 266.80 pg·h/ml and 460.07 ± 378.78 pg·h/ml, respectively. The apparent elimination half-life (t1/2) showed a mean of 8.98 ± 3.92 h. None of the adverse events that affected three subjects (16.7%) were related to the study drug.
The ability to detect the low plasma abiraterone acetate concentrations, in addition to abiraterone, resulted in a complete characterization of the pharmacokinetics of abiraterone acetate that was not possible with other analytical methods that only measured the metabolite. The development of new bioanalytical methods such as these will allow for a more thorough understanding of the pharmacokinetics of abiraterone acetate, and this, in turn, can have an impact on both future examinations into abiraterone acetate pharmacokinetic behaviour and the evaluation of its generic formulations.
The authors acknowledge the assistance provided by Ashraf El Sheikh Ali in the preparation of the manuscript.
Compliance with Ethical Standards
This study was funded by Pharma Medica Research Inc.
Conflict of interest
Mohammed Bouhajib and Zia Tayab are employees of Pharma Medica Research Inc. They do not have any other conflicts of interest to declare.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study protocol and informed consent form were approved by Salus Institutional Review Board (IRB), Texas, USA.
Informed consent was obtained from all individual participants included in the study, prior to any activity in the trial.
- 1.Janssen Biotech, Inc. Highlights of prescribing information. Zytiga® (abiraterone acetate) tablets. U.S. FDA revised 02/2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202379s024lbl.pdf. Accessed 1 Mar 2018.
- 2.Janssen-Cilag International NV. Summary of product characteristics Zytiga 250 mg tablets. EMA updated: 11/2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002321/WC500112858.pdf. Accessed 30 Mar 2018. Accessed 01 Mar 2018.
- 3.Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small E. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010. https://doi.org/10.1200/JCO.2009.24.1281.Google Scholar
- 4.National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management, clinical guideline. 2014. https://www.nice.org.uk/guidance/CG175?UNLID=. Accessed 1 Mar 2018.
- 5.National Institute for Health and Care Excellence. Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen. 2016. https://www.nice.org.uk/guidance/ta259. Accessed 1 Mar 2018.
- 6.United States Department of Health and Human Services, Food and Drug Administration. Draft guidance on abiraterone acetate. 2016. https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm333001.pdf. Accessed 1 Mar 2018.
- 7.European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on the investigation of bioequivalence. 2010. https://www.ema.europa.eu/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf. Accessed 6 Jan 2019.
- 8.United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA: draft guidance. 2013. https://www.fda.gov/downloads/drugs/guidances/ucm377465.pdf. Accessed 26 Mar 2018.
- 9.United States Department of Health and Human Services, Food and Drug Administration. Guidance for industry: bioanalytical method validation: draft guidance. 2013. https://www.fda.gov/downloads/drugs/guidances/ucm070107.Pdf. Accessed 26 Mar 2018.
- 10.European Medicines Agency. Guideline on bioanalytical method validation: draft guidance. 2011. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf. Accessed 26 Mar 2018.
- 11.International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: clinical safety data management: definitions and standards for expedited reporting: E2A. 1994. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf. Accessed 23 Feb 2018.
- 12.Benoist GE, Hendriks RJ, Mulders PF, Gerritsen WR, Somford DM, Schalken JA, van Oort IM, Burger DM, van Erp NP. Pharmacokinetic aspects of the two novel oral drugs used for metastatic castration-resistant prostate cancer: abiraterone acetate and enzalutamide. Clin Pharmacokinet. 2016. https://doi.org/10.1007/s40262-016-0403-6.Google Scholar
- 15.Pushpa Latha E, BushraY Sayeda, Navaya Sri O, Juveriya N, Anusha M, Mani Sagar G, Samuel Shine S. A review on analytical methods for estimation of abiraterone acetate. WJPMR. 2016;2(2):23–5.Google Scholar
- 17.Gurav S, Punde R, Farooqui J, Zainuddin M, Rajagopal S, Mullangi R. Development and validation of a highly sensitive method for the determination of abiraterone in rat and human plasma by LC–MS/MS-ESI: application to a pharmacokinetic study. Biomed Chromatogr. 2012;26(6):761–8.CrossRefGoogle Scholar
- 19.Belleville T, Noé G, Huillard O, Thomas-Schoemann A, Vidal M, Goldwasser F, Alexandre J, Blanchet B. A HPLC-fluorescence method for the quantification of abiraterone in plasma from patients with metastatic castration-resistant prostate cancer. J Chromatogr B. 2015. https://doi.org/10.1016/j.jchromb.2015.03.001.Google Scholar
- 21.van Nuland M, Hillebrand MJX, Rosing H, Schellens JHM, Beijnen JH. Development and validation of an LC–MS/MS method for the simultaneous quantification of abiraterone, enzalutamide, and their major metabolites in human plasma. Ther Drug Monit. 2017. https://doi.org/10.1097/FTD.0000000000000387.Google Scholar